Physician profile
Mitzi Floyd
NPI 1356713903
$6,848.68
in general payments reported to CMS, 2019-2025
17 companies · $1,672 in 2025
The $1,672 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $958 · 2022: $1,079 · 2023: $1,665 · 2024: $1,475 · 2025: $1,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,589 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,589.32 |
| Education | $222.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,172.78 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $959.16 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $887.02 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $614.38 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $547.53 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $523.66 | 2021-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $495.40 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $330.69 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Tris Pharma INC | $259.51 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $252.03 | 2021-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $219.73 | 2021-2025 | Trintellix |
| Alkermes, INC. | $146.24 | 2021-2024 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $136.10 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $112.24 | 2023-2025 | Auvelity |
| Indivior INC. | $111.50 | 2023-2024 | Perseris |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $67.45 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitzi Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.